EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics

Nicolas Picard iD, Estelle Ayme-Dietrich, Sylvie Quaranta, Tiphaine Adam-De-Beaumais, Abd El Kader Ait Tayeb iD, Hugo Alarcan, Dorra Amor, David Barthelemy, Mouna Ben Sassi, Séverine Cunat, Mouna Daldoul, Hervé Delacour und 18 weitere

Fundamental & Clinical Pharmacology · 2026

DOI: 10.1111/fcp.70068 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Fundamental & Clinical Pharmacology, 2026. Verfasst von Nicolas Picard und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Pharmacovigilance, Inserm 1248 P&T, CHU Limoges, Limoges, France. Hauptthemen laut MEDLINE: Pharmacogenetics, Pharmacogenomic Testing, Genotyping Techniques. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The implementation of pharmacogenetics in clinical practice increasingly relies on multigene panels.

Objectives

The objective of this study is to develop harmonized recommendations for the design and analytical implementation of multigene pharmacogenetic panels, defining clinically relevant genes and associated regions of interest (ROIs) based on evidence strength, therapeutic applicability, and compatibility with genotyping or sequencing technologies.

Methods

The French‐Speaking Network of Pharmacogenetics (RNPGx) evaluated 81 candidate genes across five therapeutic domains (i.e., oncology and supportive care, anesthesia and pain management, cardiology, neurology and psychiatry and immunology and infectious diseases) using a structured, evidence‐based scoring system. Each gene was evaluated using a 25‐point scoring system integrating pharmacogenetic importance, regulatory and professional society recommendations, and expert consensus. For the genes ultimately selected for the core panel, clinically relevant regions of interest were defined and assigned to one of three analytical classes. Class 1 includes variants with established clinical actionability; Class 2 adds optional variants suitable for extended testing in specialized settings; and Class 3 covers broader genomic regions mainly intended for rare variant or structural analyses.

Results

A 28‐gene core panel was retained. Class 1 included 76 prioritized variants (including CYP2D6 CNV variants), and Class 2 comprised 62 additional variants (with extended analysis for CYP2D6). Class 3 eligibility was retained for 18 genes.

Conclusion

The RNPGx recommendations offer a harmonized and flexible framework for pharmacogenetic panel design and for the extraction and interpretation of pharmacogenetic data from whole‐exome or whole‐genome sequencing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacogeneticsPharmacogenomic TestingGenotyping TechniquesHumansGenotypeFrance

Stichwörter der Autor:innen

clinical implementationgenotypingnext‐generation sequencingpharmacogenetics

Autor:innen und Institutionen

  • Department of Pharmacology, Toxicology and Pharmacovigilance, Inserm 1248 P&T, CHU Limoges, Limoges, France.
  • Laboratory of Neurocardiovascular Pharmacology and Toxicology, UR7296, University Hospitals of Strasbourg, Strasbourg, France.
  • Laboratory of Molecular Biology GEnOPé / Laboratory of Pharmacokinetic and Toxicology, Timone Hospital, AP-HM, Marseille, France.
  • Department of Children and Adolescents Oncology, Gustave Roussy, Villejuif, France.
  • Department of Genomic and Pharmacogenomic Medicine, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University Hospitals, Bicêtre Hospital, Le Kremlin Bicêtre, France.
  • Inserm, Endocrine Physiology and Physiopathology, Paris-Saclay University, Le Kremlin-Bicêtre, France.

ORCID-Profile: Nicolas Picard, Abd El Kader Ait Tayeb, Louis Lebreton, Stephanie Malard, Céline Narjoz

Zitieren

APA

Picard, N., Ayme-Dietrich, E., Quaranta, S., Adam-De-Beaumais, T., Ait Tayeb, A. E. K., Alarcan, H., Amor, D., Barthelemy, D., Sassi, M. B., Cunat, S., Daldoul, M., Delacour, H., Etienne-Grimaldi, M. C., Fonrose, X., Hennart, B., Lebreton, L., Malard, S., Narjoz, C., Omezzine, A., …, & French‐Speaking Network of Pharmacogenetics (RNPGx) (2026). French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70068

Vancouver

Picard N, Ayme-Dietrich E, Quaranta S, Adam-De-Beaumais T, Ait Tayeb AEK, Alarcan H, et al. French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics. Fundamental & Clinical Pharmacology. 2026. doi:10.1111/fcp.70068

BibTeX
@article{Picard2026,
  author = {Picard, Nicolas and Ayme-Dietrich, Estelle and Quaranta, Sylvie and Adam-De-Beaumais, Tiphaine and Ait Tayeb, Abd El Kader and Alarcan, Hugo and Amor, Dorra and Barthelemy, David and Sassi, Mouna Ben and Cunat, Séverine and Daldoul, Mouna and Delacour, Hervé and Etienne-Grimaldi, Marie-Christine and Fonrose, Xavier and Hennart, Benjamin and Lebreton, Louis and Malard, Stephanie and Narjoz, Céline and Omezzine, Asma and Pallet, Nicolas and Payen, Léa and Petit, Jeanne and Thomas, Fabienne and Trabelsi, Sameh and Tron, Camille and Verstuyft, Céline and Vilquin, Paul and Boyer, Jean-Christophe and Haufroid, Vincent and French‐Speaking Network of Pharmacogenetics (RNPGx), French‐Speaking Network of Pharmacogenetics (RNPGx)},
  title = {French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2026},
  doi = {10.1111/fcp.70068}
}
Kostenlos starten →